A systematic review on drug interactions in oncology

Cancer Investigation

Volumn 24, Issue 7, 2006, Pages 704-712

  Riechelmann, Rachel P ^a   Saad, Everardo D ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Dendrix Research   (Brazil)

Author keywords

Adverse effects; Combination; Drug interactions; Drug therapy; Neoplasms

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; BUSULFAN; CARBAMAZEPINE; CARMUSTINE; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; FLUCONAZOLE; FLUOROURACIL; GEFITINIB; IRINOTECAN; KETOCONAZOLE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NORTRIPTYLINE; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; UNINDEXED DRUG; WARFARIN;

BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CROSS REACTIVITY; DRUG FATALITY; GRANULOCYTOPENIA; HUMAN; MEGALOBLASTIC ANEMIA; META ANALYSIS; ONLINE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 33751505319     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601063766     Document Type: Review

References (100)

1. Bjerrum, L.; Andersen, M.; Petersen, G.; Kragstrup, J.. Exposure to potential drug interactions in primary health care. Scand. J. Prim. Health Care 2003, 21 (3), 153-158.
2. Carbonin, P.; Pahor, M.; Bernabei, R.; Sgadari, A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J. Am. Geriatr. Soc. 1991, 39 (11), 1093-1099.
3. Delafuente, J. C. Understanding and preventing drug interactions in elderly patients. Crit. Rev. Oncol. Hematol. 2003, 48 (2), 133-143.
4. Herr, R. D.; Caravati, E. M.; Tyler, L. S.; Iorg, E.; Linscott, M,S. Prospective evaluation of adverse drug interactions in the emergency department. Ann. Emerg. Med. 1992, 21 (11), 1331-1336.
5. Tatro, D. S. (Ed.). Drug Interaction Facts, 4th ed; Facts and Comparisons: St. Louis, MO, 1994.
6. Chabner, B. A.; Allegra, C. J.; Curt, G. A.; Calabresi, P. Antineoplastic agents. In Goodman & Gilman's The Pharmacoligical Basis of Therapeutics, Hardman, J.G., et al. (Eds.); McGraw-Hill: New York, 1996, 9th ed., pp.1233-1287.
7. Cockshott, I. D. Bicalutamide, clinical pharmacokinetics and metabolism. Clin. Pharmacokinet. 2004, 43 (13), 855-878.
8. Lonning, P.; Pfister, C.; Martoni, A.; Zamagni, C. Pharmacokinetics of third-generation aromatase inhibitors. Semin. Oncol. 2003, 30 (4 Suppl. 14), 23-32.
9. Hidalgo, M.; Bloedow, D. Pharmacokinetics and pharmacodynamics, maximizing the clinical potential of Erlotinib (Tarceva). Semin. Oncol. 2003, 3 (3 Suppl. 7), 25-33.
10. Ranson, M.; Wardell, S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J. Clin. Pharm. Ther. 2004, 29 (2), 95-103.
11. O'Brien, S. G.; Meinhardt, P.; Bond, E.; et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br. J. Cancer 2003, 89 (10), 1855-1859.
12. Trissel, L. A. Trissel's Stability of Compounded Formulations. American Pharmaceutical Association, University of Texas: Houston, 2005, 3rd ed.
13. Buajordet, I.; Ebbesen, J.; Erikssen, J.; Brors, O.; Hilberg, T. Fatal adverse drug events, the paradox of drug treatment. J. Intern. Med. 2001, 250 (4), 327-341.
14. Extermann, M. Y.; J.; Overcash, J.; Wallace, K.; et al. Influence of p450-metabolized concomitant medications on toxicity from chemotherapy in older cancer patients. Proc. Am. Soc. Clin. Oncol. 2003, 22 (Abstr. 2937), 730.
15. Riechelmann, R. P.; Moreira, F.; Smaletz, O.; Saad, E. D. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother. Pharmacol. 2005, 56 (3), 286-290.
16. Health, W. K. Drug interaction facts on eFacts online. Available at: www. factsandcomparisons.com; accessed October 2003.
17. Barrons, R. Evaluation of personal digital assistant software for drug interactions. Am. J. Health Syst. Pharm. 2004, 61 (4), 380-385.
18. Gerson, L. B. Triadafilopoulos G. proton pump inhibitors and their drug interactions, an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 2001, 13 (5), 611-616.
19. Lackner, T. E. Interaction of dexamethasone with phenytoin. Pharmacotherapy 1991, 11 (4), 344-347.
20. National Comprehensive Cancer Network. Practice Guidelines in Oncology, Antiemesis. Available at: www.nccn.org; accessed October 2005.
21. Dando, T. M.; Perry, C. M. Aprepitant, a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004, 64 (7), 777-794.
22. McCrea, J. B.; Majumdar, A. K.; Goldberg, M. R.; et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. 2003, 74 (1), 17-24.
23. Majumdar, A. K.; McCrea, J. B.; Panebianco, D. L.; et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther. 2003, 74 (2), 150-156.
24. Hylek, E. M.; Heiman, H.; Skates, S. J.; Sheehan, M. A.; Singer, D. E. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998, 279 (9), 657-662.
25. Boeijinga, J. J.; Boerstra, E. E.; Ris, P.; Breimer, D. D.; Jeletich-Bastiaanse, A. Interaction between paracetamol and coumarin anticoagulants. Lancet 1982, 1 (8270), 506.
26. Williams, J. R.; Griffin, J. P.; Parkins, A. Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. Q. J. Med. 1976, 45 (177), 63-73.
27. Duncan, D.; Sayal, K.; McConnell, H.; Taylor, D. Antidepressant interactions with warfarin. Int. Clin. Psychopharmacol. 1998, 13 (2), 87-94.
28. Sabbe, J. R.; Sims, P. J.; Sims, M. H. Tramadol-warfarin interaction. Pharmacotherapy 1998, 18 (4), 871-873.
29. Scher, M. L.; Huntington, N. H.; Vitillo, J. A. Potential interaction between tramadol and warfarin. Ann. Pharmacother. 1997, 31 (5), 646-647.
30. Black, D. J.; Kunze, K. L.; Wienkers, L. C.; et al. Warfarin-fluconazole. II. a metabolically based drug interaction, in vivo studies. Drug Metab. Dispos. 1996, 24 (4), 422-428.
31. Massey, E. W. Effect of carbamazepine on Coumadin metabolism. Ann. Neurol. 1983, 13 (6), 691-692.
32. Udall, J. A. Clinical implications of warfarin interactions with five sedatives. Am. J. Cardiol. 1975, 35 (1), 67-71.
33. Charasson, V.; Haaz, M. C.; Robert, J. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab. Dispos. 2002, 30 (6), 731-733.
34. Prados, M. D.; Yung, W. K.; Jaeckle, K. A.; et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma, a North American Brain Tumor Consortium study. Neuro-Oncol. 2004, 6 (1), 44-54.
35. Chang, S. M.; Kuhn, J. G.; Rizzo, J.; et al. Phase I study of paclitaxel in patients with recurrent malignant glioma, a North American Brain Tumor Consortium report. J. Clin. Oncol. 1998, 16 (6), 2188-2194.
36. Kehrer, D. F.; Mathijssen, R. H.; Verweij, J.; de Bruijn, P.; Sparreboom, A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 2002, 20 (14), 3122-3129.
37. Grossman, S. A.; Sheidler, V. R.; Gilbert, M. R. Decreased phenytoin levels in patients receiving chemotherapy. Am. J. Med. 1989, 87 (5), 505-510.
38. Murray, L. S.; Jodrell, D. I.; Morrison, J. G.; et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer, preliminary evidence of a potentially common drug interaction. Clin. Oncol.. (R. Coll. Radiol.) 1998, 10 (1), 35-38.
39. Harvey, V. J.; Slevin, M. L.; Dilloway, M. R.; Clark, P. I.; Johnston, A.; Lant, A. F. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br. J. Clin. Pharmacol. 1984, 18 (3), 421-430.
40. Sviland, L.; Robinson, A.; Proctor, S. J.; Bateman, D. N. Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother. Pharmacol. 1987, 20 (2), 173-175.
41. Zimms, S.; Collins, J. M.; O'Neill, D.; Chabner, B. A.; Poplack, D. G. Inhibition of first-pass metabolism in cancer chemotherapy, interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983, 34 (6), 810-817.
42. Rowinsky, E. K.; Gilbert, M. R.; McGuire, W. P.; et al. Sequences of taxol and cisplatin, a phase I and pharmacologic study. J. Clin. Oncol. 1991, 9 (9), 1692-1703.
43. Moreira, A.; Lobato, R.; Morais, J.; et al. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother. Pharmacol. 2001, 48 (4), 333-337.
44. Danesi, R.; Innocenti, F.; Fogli, S.; et al. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br. J. Clin. Pharmacol. 2002, 53 (5), 508-518.
45. Grasselli, G.; Vigano, L.; Capri, G.; et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J. Clin. Oncol. 2001, 19 (8), 2222-2231.
46. Falcone, A.; Di Paolo, A.; Masi, G.; et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol. 2001, 19 (15), 3456-3462.
47. Saltz, L. B.; Kanowitz, J.; Kemeny, N. E.; et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 1996, 14 (11), 2959-2967.
48. Correale, P.; Cerretani, D.; Clerici, M.; et al. Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies. J. Chemother. 2004, 16 (2), 206-210.
49. Boyer, E. W.; Shannon, M. The serotonin syndrome. N. Engl. J. Med. 2005, 352 (11), 1112-1120.
50. Gear, R. W.; Miaskowski, C.; Heller, P.H.; Paul, S.M.; Gordon, N.C.; Levine, J.D. Benzodiazepine mediated antagonism of opioid analgesia. Pain 1997, 71 (1), 25-29.
51. Pick, C. G. Antinociceptive interaction between alprazolam and opioids. Brain Res. Bull. 1997, 42 (3), 239-243.
52. Perez, E. A.; Rodeheffer, R. Clinical cardiac tolerability of trastuzumab. J. Clin. Oncol. 2004, 22 (2), 322-329.
53. Lunardi, G.; Vannozzi, M. O.; Bighin, C.; et al. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann. Oncol. 2003, 14 (8), 1222-1226.
54. Relling, M. V.; Pui, C.H.; Sandlund, J. T.; et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000, 356 (9226), 285-290.
55. Rodman, J. H.; Murry, D. J.; Madden, T.; Santana, V. M. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J. Clin. Oncol. 1994, 12 (11), 2390-2397.
56. Bardakji, Z.; Jolivet, J.; Langelier, Y.; Besner, J. G.; Ayoub, J. 5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. Cancer Chemother. Pharmacol. 1986, 18 (2), 140-144.
57. Volkin, R. L.; Shadduck, R. K.; Winkelstein, A.; Zeigler, Z. R.; Selker, R. G. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch. Intern. Med. 1982, 142 (2), 243-245.
58. Brown, M. C. An adverse interaction between warfarin and 5-fluorouracil, a case report and review of the literature. Chemotherapy 1999, 45 (5), 392-395.
59. Kolesar, J. M.; Johnson, C. L.; Freeberg, B. L.; Berlin, J. D.; Schiller, J. H. Warfarin-5-FU interaction-a consecutive case series. Pharmacotherapy 1999, 19 (12), 1445-1449.
60. Isaacs, K.; Haim, N. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding, case report and review of the literature. J. Chemother. 2005, 17 (3), 339-342.
61. Martin, L. A.; Mehta, S. D. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy 2003, 23 (2), 260-264.
62. Spiers, A. S.; Mibashan, R. S. Letter, Increased warfarin requirement during mercaptopurine therapy, a new drug interaction. Lancet 1974, 2 (7874), 221-222.
63. Hall, G.; Lind, M. J.; Huang, M.; et al. Intravenous infusions of ifosfamide/ mesna and perturbation of warfarin anticoagulant control. Postgrad. Med. J. 1990, 66 (780), 860-861.
64. Tenni, P.; Lalich, D. L.; Byrne, M. J. Life threatening interaction between tamoxifen and warfarin. Br. Med. J. 1989, 298 (6666), 93.
65. Lodwick, R.; McConkey, B.; Brown, A.M. Life threatening interaction between tamoxifen and warfarin. Br. Med. J. (Clin. Res. Ed.) 1987, 295 (6606), 1141.
66. Ritchie, L. D.; Grant, S. M. Tamoxifen-warfarin interaction, the Aberdeen Hospitals drug file. Br. Med. J. 1989, 298 (6682), 1253.
67. Masci, G.; Magagnoli, M.; Zucali, P. A.; et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients, can it be safely associated with fluorouracil-based chemotherapy? J. Clin. Oncol. 2003, 21 (4), 736-739.
68. Bower, M.; McCall-Peat, N.; Ryan, N.; et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004, 104 (9), 2943-2946.
69. Nilsson, C.; Aschan, J.; Hentschke, P.; et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 31 (6), 429-435.
70. Balis, F. M. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin. Pharmacokinet. 1986, 11 (3), 223-235.
71. Loadman, P. M.; Bibby, M. C. Pharmacokinetic drug interactions with anticancer drugs. Clin. Pharmacokinet. 1994, 26 (6), 486-500.
72. Sleijfer, S.; van der Mark, T. W.; Schraffordt Koops, H.; Mulder, N. H. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur. J. Cancer 1996, 32A (3), 550-552.
73. Lee, E. J.; Egorin, M. J.; Van Echo, D. A.; et al. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J. Nat. Cancer Inst. 1988, 80 (2), 131-135.
74. Davidson, K. W.; Kahn, A.; Price, R. D. Reduction of adverse drug reactions by computerized drug interaction screening. J. Fam. Pract. 1987, 25 (4), 371-375.
75. Egger, S. S.; Drewe, J.; Schlienger, R. G. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur. J. Clin. Pharmacol 2003, 58 (11), 773-778.
76. Fromm, M. F.; Eckhardt, K.; Li, S.; et al. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 1997, 72 (1-2), 261-267.
77. Zimm, S.; Collins, J. M.; O'Neill, D.; Chabner, B. A.; Poplack, D. G. Inhibition of first-pass metabolism in cancer chemotherapy, interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983, 34 (6), 810-817.
78. Culy, C. R.; Faulds, D. Gefitinib. Drugs 2002, 62 (15), 2237-2248; see discussion 49-50.
79. Abbas, R. F. S.; Riek, M.; Bulsara, S.; et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc. Am. Soc. Clin. Oncol. 2003, 22 (Abstr. 548), 137.
80. Brickell, K.; Porter, D.; Thompson, P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine), three case reports. Br. J. Cancer 2003, 89 (4), 615-616.
81. Gilbar, P. J.; Brodribb, T.R. Phenytoin and fluorouracil interaction. Ann. Pharmacother. 2001, 35 (11), 1367-1370.
82. Gajjar, A.; Kirstein, M. N.; Santana, V. M.; Furman, W. L.; et al. Concomitant dexamethasone (DXM) increases topotecan (TPT) clearance in children. Proc. Am. Soc. Clin. Oncol. 2001, 20 (Abstr. 296).
83. Engels, F. K.; Ten Tije, A. J.; Baker, S. D.; et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol Ther. 2004, 75 (5), 448-454.
84. Stolbach, L.; Begg, C.; Bennett, J. M.; et al. Evaluation of bone marrow toxic reaction in patients treated with allopurinol. JAMA 1982, 247 (3), 334-336.
85. Cagnoni, P. J.; Matthes, S.; Day, T. C.; et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999, 24 (1), 1-4.
86. Gilbert, C. J.; Petros, W. P.; Vredenburgh, J.; et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother. Pharmacol. 1998, 42 (6), 497-503.
87. Copur, M. S.; Ledakis, P.; Bolton, M.; et al. An adverse interaction between warfarin and capecitabine, a case report and review of the literature. Clin. Colorectal Cancer 2001, 1 (3), 182-184.
88. Osowski, C. L.; Dix, S. P.; Lin, L. S.; et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996, 61 (8), 1268-1272.
89. Shord, S. S.; Faucette, S. R.; Gillenwater, H. H.; et al. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2003, 51 (4), 328-336.
90. Hassan, M.; Ljungman, P.; Ringden, O.; et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite, time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000, 25 (9), 915-924.
91. Thirion, P.; Michiels, S.; Pignon, J.P.; et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer, an updated meta-analysis. J. Clin. Oncol. 2004, 22 (18), 3766-3775.
92. Borsi, J. D.; Sagen, E.; Romslo, I.; Moe, P. J. Rescue after intermediate and high-dose methotrexate, background, rationale, and current practice. Pediatr. Hematol. Oncol. 1990, 7 (4), 347-363.
93. Ferrazzini, G.; Klein, J.; Sulh, H.; et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J. Pediatr. 1990, 117 (5), 823-826.
94. Dundee, J. W.; Halliday, N. J.; McMurray, T. J.; Harper, K. W. Pre-treatment with opioids. The effect on thiopentone induction requirements and on the onset of action of midazolam. Anaesthesia 1986, 41 (2), 159-161.
95. Manara, A. R.; Shelly, M. P.; Quinn, K.; Park, G. R. The effect of metoclopramide on the absorption of oral controlled release morphine. Br. J. Clin. Pharmacol. 1988, 25 (4), 518-521.
96. Santillan, R.; Hurle, M. A.; Armijo, J. A.; de los Mozos, R.; Florez, J. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation, a double-blind, placebo-controlled study. Pain 1998, 76 (1-2), 17-26.
97. Bruera, E.; Chadwick, S.; Brenneis, C.; Hanson, J.; MacDonald, R. N. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat. Rep. 1987, 71 (1), 67-70.
98. Hermine, O.; Allard, I.; Levy, V.; et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 2002, 3 (6), 276-282.
99. Fisher, A. A.; Davis, M. W. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann. Pharmacother 2002, 36 (1), 67-71.
100. Christensen, R. C.; Byerly, M. J. Mandibular dystonia associated with the combination of sertraline and metoclopramide. J. Clin. Psychiatry 1996, 57 (12), 596.